KALA BIO, Inc.
$0.2
▲
4.42%
2026-04-21 07:41:01
www.kalarx.com
NCM: KALA
Explore KALA BIO, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$185.9 M
Current Price
$0.2
52W High / Low
$20.6 / $0.15
Stock P/E
—
Book Value
$-1.17
Dividend Yield
—
ROCE
-88.86%
ROE
-388.29%
Face Value
—
EPS
$-5.64
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
38
Beta
-1.99
Debt / Equity
2.62
Current Ratio
0.74
Quick Ratio
3.11
Forward P/E
-0.03
Price / Sales
—
Enterprise Value
$10.51 M
EV / EBITDA
-0.25
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Kodiak Sciences Inc. | $46.44 | — | $2.87 B | — | -76.6% | -1.49% | $47.41 / $2.34 | $2.55 |
| 2. | Novavax, Inc. | $8.67 | 3.2 | $1.41 B | — | 76.84% | -117.16% | $11.97 / $5.8 | $-0.79 |
| 3. | TG Therapeutics, Inc. | $36.96 | 12.6 | $5.64 B | — | 13.56% | 1.03% | $46.48 / $25.28 | $4.52 |
| 4. | Ascentage Pharma Group Internat | $25.65 | — | $18.58 B | — | -25.48% | -1.55% | $95.35 / $36.5 | $0.52 |
| 5. | Dermata Therapeutics, Inc. | $1.34 | — | $5.47 M | — | -124.91% | -1.94% | $9.9 / $1.1 | $2.34 |
| 6. | Rocket Pharmaceuticals, Inc. | $3.86 | — | $421.21 M | — | -76.11% | -60.27% | $8.26 / $2.19 | $2.56 |
| 7. | Elicio Therapeutics, Inc. | $12.2 | — | $224.43 M | — | -210.11% | 817.92% | $14.93 / $4.7 | $0.09 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -10.18 M | -10.33 M | -8.3 M | -7.26 M | -7.62 M |
| Net Profit | -7.56 M | -11.15 M | -8.95 M | -8.18 M | -8.95 M |
| EPS in Rs | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 3.89 M | 11.24 M |
| Operating Profit | -34.23 M | -34.33 M | -81.36 M | -109.43 M |
| Net Profit | -38.51 M | -42.2 M | -44.82 M | -142.6 M |
| EPS in Rs | -0.04 | -0.05 | -0.05 | -0.16 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 55.48 M | 55.95 M | 86.82 M | 139.43 M |
| Total Liabilities | 43.15 M | 48.45 M | 67.85 M | 122.62 M |
| Equity | 12.33 M | 7.5 M | 18.97 M | 16.8 M |
| Current Assets | 52.8 M | 52.87 M | 85.94 M | 124.37 M |
| Current Liabilities | 16.96 M | 8.35 M | 25.68 M | 37.42 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -29.38 M | -27.93 M | -78.91 M | -108.23 M |
| Investing CF | -0.21 M | -0.43 M | 62.72 M | 70.8 M |
| Financing CF | 29.88 M | 8.51 M | -7.94 M | 42.55 M |
| Free CF | -29.59 M | -28.54 M | -79.22 M | -113.77 M |
| Capex | -0.21 M | -0.61 M | -0.31 M | -5.54 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | -65.37% | — |
| Earnings Growth % | 8.74% | 5.85% | 68.57% | — |
| Profit Margin % | — | — | -1151.64% | -1268.73% |
| Operating Margin % | — | — | -2090.34% | -973.6% |
| Gross Margin % | — | — | 34.22% | 63.55% |
| EBITDA Margin % | — | — | -951.16% | -1185.5% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-10-21 | 1:0.02 |